Published in BMC Cancer on March 21, 2012
Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett (2013) 1.51
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med (2013) 0.98
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther (2013) 0.88
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev (2016) 0.86
Vesicular transport of progeny parvovirus particles through ER and Golgi regulates maturation and cytolysis. PLoS Pathog (2013) 0.86
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future (2016) 0.84
Production, purification, crystallization and structure determination of H-1 Parvovirus. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.84
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer (2014) 0.83
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol (2014) 0.82
Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients. Front Bioeng Biotechnol (2015) 0.81
TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells. PLoS One (2013) 0.80
Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids. J Virol (2013) 0.80
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther (2015) 0.79
Cell cycle S phase markers are expressed in cerebral neuron nuclei of cats infected by the Feline Panleukopenia Virus. Cell Cycle (2016) 0.78
Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Ther Deliv (2015) 0.78
PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis. PLoS Pathog (2015) 0.78
Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. Comp Med (2015) 0.78
Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics (2017) 0.78
Exosomes as Tools to Suppress Primary Brain Tumor. Cell Mol Neurobiol (2016) 0.77
Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme. Int J Nanomedicine (2015) 0.77
Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics (2015) 0.77
Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1. Comp Med (2015) 0.76
Can Parvovirus B19 infection be naturally oncolytic: clinical findings raise such a possibility in leukaemic children. Indian J Med Res (2014) 0.76
The Methanol Extract of Angelica sinensis Induces Cell Apoptosis and Suppresses Tumor Growth in Human Malignant Brain Tumors. Evid Based Complement Alternat Med (2013) 0.76
Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. Onco Targets Ther (2013) 0.76
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches. Front Oncol (2017) 0.75
Profiling of Host Cell Response to Successive Canine Parvovirus Infection Based on Kinetic Proteomic Change Identification. Sci Rep (2016) 0.75
Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy (2017) 0.75
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. Oncolytic Virother (2015) 0.75
Oncolytic parvoviruses: from basic virology to clinical applications. Virol J (2015) 0.75
Induction of an embryonic mouse innate immune response following inoculation in utero with minute virus of mice. J Virol (2014) 0.75
Emerging role of Natural killer cells in oncolytic virotherapy. Immunotargets Ther (2015) 0.75
Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. Neurosurgery (2014) 0.75
VP2 capsid domain of the H-1 parvovirus determines susceptibility of human cancer cells to H-1 viral infection. Cancer Gene Ther (2015) 0.75
The Mammalian Cell Cycle Regulates Parvovirus Nuclear Capsid Assembly. PLoS Pathog (2015) 0.75
Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. Viruses (2016) 0.75
Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther (2017) 0.75
A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles. Appl Microbiol Biotechnol (2017) 0.75
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers. Front Oncol (2017) 0.75
Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine (2017) 0.75
Fighting Cancer with Mathematics and Viruses. Viruses (2017) 0.75
Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990) 10.19
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol (1999) 8.69
Brain tumors. N Engl J Med (2001) 8.13
Design and analysis of phase I clinical trials. Biometrics (1989) 4.31
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Biology of adeno-associated virus. Curr Top Microbiol Immunol (1996) 2.40
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther (2008) 2.17
AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther (2004) 2.15
Recent advances in therapy for glioblastoma. Arch Neurol (2010) 1.92
HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther (2004) 1.91
Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol (2006) 1.86
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther (2008) 1.81
Antineoplastic activity of parvoviruses. J Virol Methods (1991) 1.74
Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol (2007) 1.33
Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev (2010) 1.33
Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol (2003) 1.28
Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer (2004) 1.19
Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol (2010) 1.12
H-1 VIRUS VIREMIA IN THE HUMAN. Proc Soc Exp Biol Med (1965) 0.98
Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med B Infect Dis Vet Public Health (2005) 0.95
Long-term outcome of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder. Am J Psychiatry (2014) 3.32
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: a multicenter randomized controlled trial. Am J Psychiatry (2013) 2.57
Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res (2004) 2.24
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res (2006) 2.07
Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res (2008) 1.83
A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother (2009) 1.75
p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis. Cancer Cytopathol (2012) 1.60
Biomarkers in cervical cancer screening. Dis Markers (2007) 1.58
Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst (2005) 1.55
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med (2011) 1.54
Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol (2009) 1.54
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther (2010) 1.51
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer (2005) 1.48
A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene (2003) 1.42
Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res (2003) 1.42
Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg (2005) 1.41
Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res (2003) 1.40
Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst (2013) 1.38
Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res (2009) 1.36
Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol (2007) 1.33
Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev (2010) 1.33
The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res (2008) 1.30
The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. J Virol (2002) 1.30
New technologies and procedures for cervical cancer screening. Vaccine (2012) 1.29
Human SGT interacts with Bag-6/Bat-3/Scythe and cells with reduced levels of either protein display persistence of few misaligned chromosomes and mitotic arrest. Exp Cell Res (2006) 1.28
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene (2005) 1.26
Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res (2005) 1.25
Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer (2004) 1.19
Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha1 subunit in small-cell lung cancer cells. Oncogene (2003) 1.15
Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther (2005) 1.15
Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomark (2006) 1.15
BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer (2013) 1.14
The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun (2009) 1.14
Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev (2004) 1.14
T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res (2005) 1.13
Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis (2005) 1.13
Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol (2010) 1.12
Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther (2002) 1.12
Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun (2004) 1.12
Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer (2005) 1.11
Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer (2011) 1.11
Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer (2010) 1.10
Nuclear accumulation of beta-catenin protein in Wilms' tumours. J Pathol (2003) 1.08
Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep (2007) 1.06
Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol (2006) 1.06
Modulation of minute virus of mice cytotoxic activities through site-directed mutagenesis within the NS coding region. J Virol (2003) 1.04
Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. PLoS One (2011) 1.04
Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncol (2012) 1.04
A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides. Cell Oncol (2010) 1.03
SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res (2009) 1.02
A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc Natl Acad Sci U S A (2007) 1.02
Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. J Virol (2010) 1.02
Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res (2012) 1.02
Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol (2003) 1.02
DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res (2004) 1.02
NS1 interaction with CKII alpha: novel protein complex mediating parvovirus-induced cytotoxicity. J Virol (2006) 1.01
Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol (2003) 1.01
Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol Ther (2010) 1.01
Regulation of minute virus of mice NS1 replicative functions by atypical PKClambda in vivo. J Virol (2003) 1.00
Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer (2008) 1.00
Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol (2010) 1.00
Selective alterations of the host cell architecture upon infection with parvovirus minute virus of mice. Virology (2005) 1.00
Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions. Int J Cancer (2012) 1.00
Identification and characterization of UEV3, a human cDNA with similarities to inactive E2 ubiquitin-conjugating enzymes. Biochim Biophys Acta (2002) 0.99
Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning. PLoS Pathog (2008) 0.99
Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer (2004) 0.99
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med (2013) 0.98
Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther (2012) 0.98
Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Fam Cancer (2010) 0.98
The Wnt signaling pathway in solid childhood tumors. Cancer Lett (2003) 0.97
Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam Cancer (2011) 0.97
Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. Int J Cancer (2007) 0.97
The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer (2014) 0.96
Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol (2014) 0.95
Focal Delivery of AAV2/1-transgenes Into the Rat Brain by Localized Ultrasound-induced BBB Opening. Mol Ther Nucleic Acids (2013) 0.95
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability. BMC Cancer (2008) 0.95
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol (2006) 0.94
Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. Eur J Hum Genet (2006) 0.94
Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol (2007) 0.94
Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. Int J Oncol (2004) 0.94
Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther (2009) 0.94
Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. Int J Cancer (2011) 0.94
Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol (2010) 0.93
Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line. Int J Cancer (2006) 0.93
Differentiated NSC-34 motoneuron-like cells as experimental model for cholinergic neurodegeneration. Neurochem Int (2013) 0.92